↓ Skip to main content

Dove Medical Press

Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice

Overview of attention for article published in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, March 2020
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (61st percentile)
  • Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

twitter
1 X user
wikipedia
1 Wikipedia page

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
23 Mendeley
Title
Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice
Published in
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, March 2020
DOI 10.2147/dmso.s242282
Pubmed ID
Authors

Aline David-Silva, João Victor Esteves, Mychel Raony P T Morais, Helayne Soares Freitas, Telma Maria Zorn, Maria Lucia Correa-Giannella, Ubiratan Fabres Machado

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 23 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 4 17%
Student > Ph. D. Student 3 13%
Student > Postgraduate 2 9%
Other 1 4%
Professor > Associate Professor 1 4%
Other 1 4%
Unknown 11 48%
Readers by discipline Count As %
Medicine and Dentistry 5 22%
Biochemistry, Genetics and Molecular Biology 3 13%
Nursing and Health Professions 1 4%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Unknown 13 57%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 February 2022.
All research outputs
#7,994,699
of 25,462,162 outputs
Outputs from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#324
of 1,184 outputs
Outputs of similar age
#145,057
of 383,842 outputs
Outputs of similar age from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#12
of 52 outputs
Altmetric has tracked 25,462,162 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 1,184 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 383,842 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.